[HTML][HTML] Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase
MK Jathal, TM Steele, S Siddiqui, BA Mooso… - British journal of …, 2019 - nature.com
Background Despite overexpression of the ErbB (EGFR/HER2/ErbB3/ErbB4) family in
castration-resistant prostate cancer (CRPC), some inhibitors of this family, including the dual …
castration-resistant prostate cancer (CRPC), some inhibitors of this family, including the dual …
[HTML][HTML] Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer
Incurable castration-resistant prostate cancer (CRPC) is driven by androgen receptor (AR)
activation. Potent therapies that prevent AR signaling, such as Enzalutamide (ENZ), are …
activation. Potent therapies that prevent AR signaling, such as Enzalutamide (ENZ), are …
ErbB2 signaling increases androgen receptor expression in abiraterone-resistant prostate cancer
Purpose: ErbB2 signaling appears to be increased and may enhance androgen receptor
(AR) activity in a subset of patients with castration-resistant prostate cancer (CRPC), but …
(AR) activity in a subset of patients with castration-resistant prostate cancer (CRPC), but …
Antitumor effects of carnertinib in castration resistant prostate cancer models: A Comparative study with erlotinib
GL Gravina, F Marampon, M Piccolella, L Biordi… - The …, 2011 - Wiley Online Library
Abstract BACKGROUND AND PURPOSE Although preclinical results suggest that the
inhibition of erb‐B1 or erb‐B2 can be an useful tool to castration resistant prostate cancer …
inhibition of erb‐B1 or erb‐B2 can be an useful tool to castration resistant prostate cancer …
A phase II trial of lapatinib in hormone refractory prostate cancer
YE Whang, CN Moore, AJ Armstrong… - Journal of Clinical …, 2008 - ascopubs.org
16037 Background: Epidermal growth factor receptor (EGFR) and human epidermal growth
factor receptor 2 (HER2) tyrosine kinases represent potential targets in prostate cancer …
factor receptor 2 (HER2) tyrosine kinases represent potential targets in prostate cancer …
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
OBJECTIVES:: Epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases may
be involved in activation of androgen receptor and progression of prostate cancer. They …
be involved in activation of androgen receptor and progression of prostate cancer. They …
[HTML][HTML] Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells
CE Fonseca-Alves, AF Leis-Filho, ZA Lacerda… - Plos one, 2024 - journals.plos.org
The aberrant activation of HER2 has a pivotal role in bone metastasis implantation and
progression in several tumor types, including prostate cancer (PC). Trastuzumab and other …
progression in several tumor types, including prostate cancer (PC). Trastuzumab and other …
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer
Objectives: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of
the epidermal growth factor 1 (EGFR) and 2 (HER2), approved in the treatment of HER2 …
the epidermal growth factor 1 (EGFR) and 2 (HER2), approved in the treatment of HER2 …
[HTML][HTML] ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity …
JE Vellky, BJ Kirkpatrick, LC Gutgesell, M Morales… - Clinical Cancer …, 2024 - AACR
Purpose: Despite successful clinical management of castration-sensitive prostate cancer
(CSPC), the 5-year survival rate for men with castration-resistant prostate cancer is only …
(CSPC), the 5-year survival rate for men with castration-resistant prostate cancer is only …
Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3
L Chen, BA Mooso, MK Jathal, A Madhav… - Clinical Cancer …, 2011 - AACR
Purpose: Patients with recurrent prostate cancer are commonly treated with androgen
withdrawal therapy (AWT); however, almost all patients eventually progress to castration …
withdrawal therapy (AWT); however, almost all patients eventually progress to castration …